Search results
400 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Able Wealth Management LLC
ETF DAILY NEWS· 5 days agoAble Wealth Management LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) in the 4th quarter, HoldingsChannel.com reports.
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
Zacks via Yahoo Finance· 4 hours agoThe European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for...
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer - AstraZeneca (NASDAQ:AZN)
Benzinga· 3 days agoAstraZeneca plc’s AZN cancer drug, Imfinzi (durvalumab), in conjunction with standard chemotherapy,...
Wellington Management Group LLP Has $3.33 Billion Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 3 days agoWellington Management Group LLP decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.1% during the 4th quarter, according ...
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Benzinga via Yahoo Finance· 2 days agoAstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug...
One AstraZeneca Insider Raised Stake By 50% In Previous Year
Simply Wall St. via Yahoo Finance· 2 days agoViewing insider transactions for AstraZeneca PLC's (LON:AZN ) over the last year, we see that...
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial - ...
Benzinga· 2 days agoTuesday, AstraZeneca Plc AZN announced topline data from the CAPItello-290 Phase 3 trial for Truqap...
Maker of COVID vaccines and naloxone exits Baltimore with sale of plant
The Baltimore Banner· 48 minutes agoGaithersburg-based Emergent BioSolutions is officially leaving Baltimore after a tumultuous stretch...
AstraZeneca’s Truqap flops in Phase III triple negative breast cancer trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAstraZeneca has been dealt a blow after its flagship breast cancer drug Truqap (capivasertib) did...
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression...
Benzinga· 3 days agoAstraZeneca Plc AZN released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus...